185 related articles for article (PubMed ID: 17935198)
21. Medication use and adherence among elderly Medicare beneficiaries with diabetes enrolled in Part D and retiree health plans.
Stuart B; Simoni-Wastila L; Yin X; Davidoff A; Zuckerman IH; Doshi J
Med Care; 2011 May; 49(5):511-5. PubMed ID: 21422956
[TBL] [Abstract][Full Text] [Related]
22. The $150 billion swindle. The case against Medicare Advantage is overwhelming; when will D.C. get wise?
Sloane T
Mod Healthc; 2007 Sep; 37(37):17. PubMed ID: 17958047
[No Abstract] [Full Text] [Related]
23. Medicare Part D: how do vulnerable beneficiaries fare?
Summer L; Nemore P; Finberg J
Issue Brief (Commonw Fund); 2008 Apr; 35():1-11. PubMed ID: 18536146
[TBL] [Abstract][Full Text] [Related]
24. Continuing effects of Medicare Part D on rural independent pharmacies who are the sole retail provider in their community.
Radford A; Mason M; Richardson I; Rutledge S; Poley S; Mueller K; Slifkin R
Res Social Adm Pharm; 2009 Mar; 5(1):17-30. PubMed ID: 19285286
[TBL] [Abstract][Full Text] [Related]
25. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
26. Changes in Medicaid prescription volume and use in the wake of Medicare Part D implementation.
Bruen BK; Miller LM
Health Aff (Millwood); 2008; 27(1):196-202. PubMed ID: 18180495
[TBL] [Abstract][Full Text] [Related]
27. Medicare program; Medicare Advantage and prescription drug benefit programs: negotiated pricing and remaining revisions. Final rule with comment period.
Fed Regist; 2009 Jan; 74(7):1493-549. PubMed ID: 19143114
[TBL] [Abstract][Full Text] [Related]
28. Should drug prices be negotiated under part D of Medicare? And if so, how?
Frank RG; Newhouse JP
Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
[TBL] [Abstract][Full Text] [Related]
29. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
30. Rural-Urban Enrollment in Part D Prescription Drug Plans: June 2017 Update.
Weigel P; Ullrich F; Mueller K
Rural Policy Brief; 2017 Dec; 2017(7):1-6. PubMed ID: 29693334
[TBL] [Abstract][Full Text] [Related]
31. Medicare part D data: major changes on the horizon.
Greenwald LM
Med Care; 2007 Oct; 45(10 Supl 2):S9-12. PubMed ID: 17909390
[TBL] [Abstract][Full Text] [Related]
32. Why using current medications to select a medicare Part D plan may lead to higher out-of-pocket payments.
Domino ME; Stearns SC; Norton EC; Yeh WS
Med Care Res Rev; 2008 Feb; 65(1):114-26. PubMed ID: 17942795
[TBL] [Abstract][Full Text] [Related]
33. How does drug treatment for diabetes compare between Medicare Advantage prescription drug plans (MAPDs) and stand-alone prescription drug plans (PDPs)?
Erten MZ; Stuart B; Davidoff AJ; Shoemaker JS; Bryant-Comstock L; Shenolikar R
Health Serv Res; 2013 Jun; 48(3):1057-75. PubMed ID: 23205568
[TBL] [Abstract][Full Text] [Related]
34. Coverage of insulin delivery devices and basal insulin analogs by US managed care organizations.
Kimball ES; Aagren M
J Med Econ; 2011; 14(6):720-8. PubMed ID: 21899485
[TBL] [Abstract][Full Text] [Related]
35. Medicare Part D--the sea of choices meets the donut hole.
Flaer PJ; Dondériz A; Younis MZ
J Health Care Finance; 2007; 34(1):1-7. PubMed ID: 18972980
[TBL] [Abstract][Full Text] [Related]
36. Medicare Part D: early findings on enrollment and choices for rural beneficiaries.
McBride TD; Terry TL; Mueller KJ
Rural Policy Brief; 2006 Apr; 10(8 (PB2006-8)):1-9. PubMed ID: 16685809
[TBL] [Abstract][Full Text] [Related]
37. Medicare Part D: simplifying the program and improving the value of information for beneficiaries.
Hoadley J
Issue Brief (Commonw Fund); 2008 May; 39():1-15. PubMed ID: 18536148
[TBL] [Abstract][Full Text] [Related]
38. Potential opportunity cost of neglecting to annually reassess Medicare Part D standalone prescription drug plan offerings: the price of contentment?
Walberg MP; Patel RA
J Am Pharm Assoc (2003); 2009; 49(6):777-82. PubMed ID: 19926558
[TBL] [Abstract][Full Text] [Related]
39. Prescription drug coverage: medicine or science?
Herbst JL
Hastings Cent Rep; 2013; 43(4):9-10. PubMed ID: 23842915
[No Abstract] [Full Text] [Related]
40. Medicare program; policy and technical changes to the Medicare prescription drug benefit. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2008 Apr; 73(73):20485-509. PubMed ID: 18464352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
